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Background. Nephrolithiasis in living kidney donors is concerning due to the potential impact on long-term postdonation kidney function. Methods. We performed a cohort study of living kidney donors from 2 centers with a baseline
computed tomography scan and implantation renal biopsy. Donors (>5 y since donation) completed a follow-up survey or
underwent chart review to assess eGFR and incident hypertension. Stone formers were classified as symptomatic if they
had a past symptomatic episode or asymptomatic if only incidental radiographic kidney stones were identified during donor
evaluation. We compared baseline clinical, imaging, and biopsy characteristics by stone former status including review of
metabolic evaluations in stone formers. Long-term risks of renal complications (low eGFR and hypertension) by stone former
status were evaluated. Results. There were 12 symptomatic and 76 asymptomatic stone formers among 866 donors.
Overall, baseline clinical characteristics and implantation biopsy findings were similar between stone formers and non-stone
formers. After a median follow-up of 10 y, stone former status was not associated with eGFR <60 mL/min/1.73 m2, eGFR
<45 mL/min/1.73 m2, or hypertension. Conclusions. Both asymptomatic and symptomatic SF have favorable histology
findings at baseline. Long-term kidney outcomes were favorable in select stone formers with no evident increased long-term
risk for decreased kidney function or hypertension after donation.
(Transplantation Direct 2022;8: e1278; doi: 10.1097/TXD.0000000000001278).

T

he incidence of symptomatic and asymptomatic kidney stone disease in the general population is on the rise.1 Therefore, it is not surprising
that as many as 13% of potential kidney donors
have a history of symptomatic nephrolithiasis or

asymptomatic kidney stones found incidentally on computed tomography (CT) scan during donor evaluation.2
In the general population, nephrolithiasis is associated with
significant long-term morbidity, including chronic kidney
disease and hypertension. 3-5 Several risk factors have been
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described to associate with future chronic kidney disease,
end-stage renal disease, and proteinuria post–living kidney donation including older age, higher body mass index
(BMI), hypertension, and subsequent diagnosis of diabetes.6
The growing need for kidney transplantation has motivated transplant centers to broaden acceptance criteria
to include medically complex living donors including
donors with history of nephrolithiasis. 7,8 Although transplant centers have developed specific acceptance criteria
for many comorbid conditions, a broad range of criteria has been implemented for potential donors with
nephrolithiasis.9-12
There are numerous guidelines for evaluating potential
living kidney donors with nephrolithiasis.11 These guidelines have evolved to allow potential donors with asymptomatic stones or a distant history of symptomatic kidney
stones to donate as long as the stone burden is low and
metabolic evaluation is unremarkable. Early postdonation
reported outcomes are favorable, including a low rate of
kidney stone recurrence.13,14 However, many of these studies were limited by short-term follow-up and small sample
size and did not address other important outcomes, including postdonation kidney function. The newly published
large study deriving from the “Renal and Lung Living
Donors Evaluation” study revealed encouraging data
that donors with a history of nephrolithiasis had similar
long-term outcomes when matched to non-stone formers.
However, it lacked granular data on stone formers (SFs)
(symptomatic versus asymptomatic), metabolic evaluation in SF, and other potential risk factors for stone recurrence.15 This data would help guide clinicians in providing
better risk assessments for donors with stones on potential
long-term complications.
The Aging Kidney Anatomy study cohort has detailed
biopsy characteristics of kidneys in living donors and their
long-term outcomes.16,17 This cohort offers a unique opportunity to study the clinical and structural characteristics of
donors with nephrolithiasis and their long-term outcomes.

MATERIALS AND METHODS
Study Design and Population
This study was approved by the Mayo Clinic Institutional
Review Board. The patients involved in our study provided
written informed consent. We surveyed adult (≥18 y old) living kidney donors from the Aging Kidney Anatomy Study16
at Mayo Clinic (Minnesota and Arizona) who underwent
donor nephrectomy from May 1, 1999 to March 1, 2013 and
who had at least 5 y of postdonation follow-up. Inclusion criteria were the availability of high-resolution CT scan images
(obtained at the time of donor evaluation) and adequate
renal implantation biopsy (with ≥2 mm2 of nondistorted cortex with ≥4 glomeruli) obtained at the time of transplant
surgery. The Mayo Clinic Survey Research Center contacted
donors via mailed surveys and follow-up phone calls from
April 1, 2017 to December 31, 2019, using Accurint (www.
accurint.com) to update contact information. Donors were
asked to complete the survey via mail or phone interview. We
requested donors provide recent (within the past 2 y) blood
pressure readings, height, weight, and serum creatinine levels, along with testing dates. We offered remuneration to
those lacking a recent blood pressure, height, weight, or
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serum creatinine to obtain these tests from a local provider.
Donors who did not complete the survey but had a clinical follow-up in the Mayo Clinic Health System had their
latest serum creatinine along with available height, weight,
and blood pressure measurements manually abstracted from
their medical records. Length of follow-up was determined
by date of kidney donation until the date of the latest GFR
measurement.
Kidney Donors With Nephrolithiasis
All donors were assessed for personal history of nephrolithiasis (including the number of prior episodes and time since the
last symptomatic episode) and the presence of asymptomatic
nephrolithiasis on evaluation CT scan. Donors with nephrolithiasis, termed SFs, were classified as symptomatic SF if they
had a prior clinical episode with or without nephrolithiasis
on CT scan during donor evaluation and asymptomatic SF
if no prior history of symptomatic stones but the presence of
asymptomatic nephrolithiasis was incidentally found during
kidney donor evaluation. Notably, none of the asymptomatic
SFs had previously known asymptomatic nephrolithiasis on
imaging before the donor evaluation. We described the stone
burden by stone location, the number of stone(s) present on
imaging, and the largest stone diameter. Donors who were not
symptomatic SF or asymptomatic SF were termed non-SF.
Donors that were SFs were evaluated according to evolving national and international protocols and guidelines over
time.11 SFs were evaluated in conjunction with a nephrologist
specializing in kidney stone disease. SFs underwent metabolic
stone evaluation and in later years a 24 h urine collection
for urine chemistries. SFs with a history of rare stone types
(eg, cysteine, struvite), nephrocalcinosis, and underlying metabolic disorders, including distal renal tubular acidosis, primary
hyperoxaluria, and enteric hyperoxaluria, were excluded from
donation. Of note, regardless of stone history, all donors with
a history of gastric bypass surgery also underwent 24 h urine
evaluation for urine oxalate, and those with high oxalate
(≥40 mg/24 h) were excluded. Potential relative contraindications to donation were abnormal metabolic evaluation (eg,
hypercalciuria), markedly low 24 h urine volume (<1000 mL),

FIGURE 1. Selection of kidney donors with long-term follow-up.
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TABLE 1.

Baseline clinical characteristics by kidney stone group

Clinical characteristics
Age (y)
Male
Caucasian
Predonation hypertension
Predonation SBP (mm Hg)
Predonation DBP (mm Hg)
Body mass index (kg/m2)
Obesity (BMI ≥ 30 kg/m2)
Total cholesterol
Triglycerides
HDL cholesterol
Fasting glucose
Metabolic syndrome
Bariatric surgery
History of urinary tract infections
Thiazide diuretic
Vitamin C supplement
Calcium supplement
Serum calcium (mg/dL)
Serum phosphorus (mg/dL)
Serum uric acid (mg/dL)
eGFR (mL/min/1.73 m2)
Measured GFR (mL/min/1.73 m2)
24 h urine albumin (mg)
24 h urine total protein (mg)
24 h urine volume (mL)
24 h urine volume <1000 mL
Donor nephrectomy—right

Group 1: non-stone
formers (N = 778),
mean ± SD or N(%)
46.6 ± 11.9
285 (36.6)
715 (91.9)
92 (11.8)
120.6 ± 14.9
72.8 ± 9.5
27.8 ± 4.8
232 (29.8)
196.2 ± 37.0
114.6 ± 68.2
59.0 ± 16.4
93.8 ± 8.6
122 (15.7)
4 (0.5)
58 (6.8)
27 (3.5)
51 (6.6)
123 (15.8)
9.6 ± 0.3
3.6 ± 0.7
5.1 ± 1.3
87.8 ± 15.0
101.5 ± 19.6
4.6 ± 7.4
258 (37.2)
2149.8 ± 947.0
59 (9.3)
149 (19.2)

Group 2: asymptomatic
stones only (N = 76),
mean ± SD or N(%)
45.6 ± 11.6
29 (38.2)
70 (92.1)
15 (19.7)
121.8 ± 15.8
74.5 ± 10.2
28.1 ± 6.0
23 (30.3)
196.9 ± 36.4
131.2 ± 105.2
55.1 ± 14.8
93.8 ± 9.1
18 (23.6)
0
6 (7.9)
8 (10.5)
4 (5.3)
11 (14.5)
9.5 ± 0.4
3.5 ± 0.6
5.3 ± 1.5
86.4 ± 14.0
99.7 ± 16.7
4.2 ± 4.6
52.7 (43.2)
2159.1 ± 822.1
5 (6.6)
23 (30.3)

Group 3: symptomatic
stone formers (N = 12),
mean ± SD or N(%)

P, group
1 vs 2

P, group
1 vs 3

50.5 ± 10.4
7 (58.3)
12 (100)
2 (16.7)
126.3 ± 11.3
73.4 ± 10.7
30.5 ± 5.9
6 (50)
190.4 ± 33.8
157.7 ± 208.9
54.5 ± 17.3
100.8 ± 19.4
4 (33.3)
1 (8.3)
2 (16.7)
0
0
3 (25)
9.5 ± 0.37
3.5 ± 1.1
5.3 ± 1.6
81.3 ± 10.5
95.1 ± 10.6
4 ± 3.7
58.3 ± 44.0
2264.3 ± 798.8
1 (8.3)
2 (16.7)

0.29
0.79
0.95
0.05
0.87
0.30
0.77
0.94
0.98
0.28
0.04
0.91
0.07
0.99
0.89
0.003
0.81
0.76
0.20
0.61
0.45
0.49
0.64
0.43
0.15
0.79
0.45
0.02

0.26
0.12
0.30
0.64
0.82
0.55
0.07
0.11
0.59
0.60
0.37
0.31
0.71
0.07
0.23
0.99
0.99
0.41
0.83
0.16
0.73
0.16
0.37
0.62
0.44
0.11
0.94
0.99

Bolded P-values - significant for P < 0.05.
BMI, body mass index; DBP, diastolic blood pressure; GFR, glomerular filtration rate; HDL, high-density lipoprotein; SBP, systolic blood pressure.

TABLE 2.

Baseline structural characteristics by kidney stone group
Structural characteristics,
mean ± SD or n (%)
Macrostructural characteristics
Medullary sponge kidney
Focal scarring
Parenchymal thinning
Nephron size and number
Glomerular volume (mm3)
Cortex volume per glomerulus (mm3)
Tubular cross-sectional area (μm2)
Nephron number per kidney
Nephrosclerosis
Globally sclerotic glomeruli (%)
Number of IF/TA foci
Range
Percentage IF/TA by age
  0%
  <1%
  1%–5%
  6%–10%
  >10%
Artery luminal stenosis (%)
Any arteriolar hyalinosis
Bolded P-values - significant for P < 0.05.
IF/TA, interstitial fibrosis/tubular atrophy.

Group 1: non-stone
formers (N = 778),
mean ± SD or N(%)

Group 2: asymptomatic
stones only (N = 76),
mean ± SD or N(%)

Group 3: symptomatic
stone formers (N = 12),
mean ± SD or N(%)

P, group
1 vs 2

P, group
1 vs 3

7 (0.9)
13 (1.7)
1 (0.1)

4 (5.3)
3 (3.9)
1 (1.3)

0
0
0

0.01
0.16
0.17

0.99
0.99
0.99

0.003 ± 0.001
0.08 ± 0.04
4533 ± 1504
863 927 ± 383 690

0.003 ± 0.001
0.07 ± 0.03
4332 ± 1626
811 576 ± 323 033

0.003 ±0.0006
0.07 ± 0.03
4672.1 ± 1358.1
886 980.7 ± 478 924.3

0.73
0.95
0.11
0.44

0.96
0.72
0.69
0.86

3.5 ± 6.4
0.5 ± 1.1
0-10

3.9 ± 6.6
0.7 ± 1.4
0-6

2.9 ± 4.7
0.2 ± 0.4
0-1

0.52
0.05

0.85
0.47

0.17

0.77

589 (75.3)
61 (7.8)
104 (13.3)
20 (2.6)
8 (1.0)
37.8 ± 12.5
7 (1.1)

52 (71.2)
8 (10.9)
10 (13.7)
3 (4.1)
0
38.1 ± 12.3
2 (3.2)

10 (83.3)
2 (16.7)
0
0
0
30.6 ± 8.9
0

0.79
0.19

0.03
0.99
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TABLE 3.

Characteristics of stone disease in stone formers

Clinical characteristics
of stone formers
Symptomatic stone history
More than 1 prior symptomatic stone
Time from last symptomatic stone to
donation (y)
Family history of stone disease
Characteristics of radiographic stones
Number of stones
  1 stone
  2 stones
  >2 stones
Range
Bilateral stones
Largest stone diameter
Stone laterality
  Right
  Left
  Bilateral
Location of stone(s)
  Lower pole
  Middle pole
  Upper pole
  Multiplea
24 h urine supersaturation studies
Two supersaturation studies
Urine pH
Urine pH <5.5 or >6.5
CaOx supersaturation (DG)
CaOx supersaturation >1.77 (DG)
CaPhos supersaturation (DG)
CaPhos supersaturation >3.96 (DG)
Urine calcium (mg/24 h)
Urine calcium ≥200 mg/24 h
Urine sodium (mmol > 24h)
Urine sodium ≥200 mmol/24 h
Urine oxalate (mg/24 h)
Urine oxalate ≥40 mg/24 h
Urine citrate (mg/24 h)
Urine citrate ≤300 mg/24 h
Urine uric acid (mg/24 h)
Urine uric acid ≥700 mg/24 h
Any 24 h urine abnormality

Asymptomatic
Symptomatic
stones only
stone formers
(N = 76), mean (N = 12), mean ±
± SD or N (%)
SD or N (%)
N/A
N/A
8 (10.5)
1.6 ± 1.7
58 (76.3)
10 (13.2)
8 (10.5)
1-12
11 (14.3)
1.8 ± 1.3
34 (44.7)
31 (40.8)
11 (14.3)
41 (53.9)
12 (15.8)
11 (14.5)
12 (15.8)
39 (51.3)
17 (22.4)
6.1 ± 0.5
24 (32.4)
1.0 ± 0.9
5 (15.6)
3.4 ± 2.1
11 (34.4)
176.1 ± 81.2
11 (28.2)
152.5 ± 65.5
11 (20.0)
24.7 ± 7.6
3 (8.1)
702.1 ± 338.0
6 (15.8)
591.5 ± 208.8
7 (21.9)
35 (81.4)

4 (25%)
11.1 ± 5.5
4 (33.3)
0.42 ± 0.99
0 (0)
1 (8.3)
1 (8.3)
0-3
2 (16.7)
3.5 ± 0.7
0
0
2 (13.6)
0
0
0
2 (16.7)
8 (66.7)
2 (16.7)
6.0 ± 0.6
4 (36.3)
1.1 ± 0.9
3 (37.5)
3.6 ± 2.0
4 (50.0)
196.4 ± 89.8
3 (37.5)
155.6 ± 80.7
3 (33.3)
24.6 ± 7.3
1 (12.5)
703.4 ± 262.2
1 (12.5)
576.3 ± 215.1
2 (25.0)
7 (87.5)

SF with multiple stones located in different regions of the kidney(s).
CaOx, calcium oxalate; CaPhos, calcium phosphate.

a

younger age (≤40 y old), significant stone burden on imaging
including bilateral stone disease, and medullary sponge kidney (MSK). Favorable characteristics that contributed to the
acceptance of symptomatic SF, particularly those with recurrent episodes, included: older age, longer time—at least 3 y—
since last episode, no evidence of stone formation on serial
imaging with prior CT scans were available for comparison),
and normal or easily correctable 24 h urine chemistries. Select
SF with an abnormal metabolic evaluation received treatment
(including thiazide diuretics or citrate supplementation) and
were approved to donate.18 All SFs received dietary education
to lower the risk of stone formation. SFs with asymptomatic
kidney stone(s) typically donated a kidney with stone(s) to

leave the donor with a stone-free kidney and reduce their risk
of a stone event long-term. Although rare, accepted SFs with
bilateral asymptomatic nephrolithiasis donated the stonebearing kidney with larger/more stone(s). Deviations from
this protocol occurred per surgeon discretion.
Available values, including urine calcium, sodium, oxalate, citrate, and uric acid, were manually abstracted from
valid 24 h urine supersaturation studies based on urine creatinine (10–29 mg/kg) collected from SFs. If multiple 24 h
urine studies were available, we reported the average values.
Supersaturation for calcium oxalate and hydroxyapatite or
calcium phosphate crystals were abstracted and calculated
using EQUIL2.19 We included the 24 h urine volume and urine
pH from the standard donor evaluation 24 h urine protein
study and urinalysis, respectively. Serum parathyroid hormone was obtained if parathyroid disease was suspected.
Donor Clinical Characteristics
Baseline data were obtained from the extensive evaluations
of kidney donors before undergoing kidney donation as previously described.16 The predonation evaluation included serum
creatinine to estimate glomerular filtration rate (eGFR),20
iothalamate clearance to measure GFR, 24 h urine albumin,
BMI, office blood pressure, and CT scan imaging of the kidneys. Acceptance criteria for donation varied by site and era, but
in general included 24 h urine albumin excretion <30 mg and
a measured glomerular filtration rate (GFR) normal for age.
Mild hypertension in older donors and moderate obesity (BMI
30–35 kg/m2; occasionally up to 40 kg/m2 in older donors) were
allowed. Hypertension was defined as a preexisting diagnosis of
hypertension, an office systolic blood pressure ≥140 mm Hg or
diastolic blood pressure ≥90 mm Hg, or the use of antihypertensive medication(s) to treat hypertension. Acceptable predonation “mild” hypertension was defined by either office blood
pressure of 140–159/90–99 mm Hg or controlled with 1 antihypertensive medication (with or without a thiazide diuretic). Of
note, all thiazide diuretics at baseline were being used to treat
hypertension before donation and not for stone prevention.
Microstructural and Macrostructural Characteristics
of Donors
As part of routine clinical care, intraoperative needle core
biopsy of the renal cortex was performed at the time of transplantation. The tissue specimen was fixed in formalin and
embedded in paraffin. Two sections (2–3 μm thickness) from
the biopsy core were stained, 1 with periodic acid–Schiff and
1 with Masson trichrome, and were subsequently scanned
into high-resolution digital images (Aperio XT digital scanner;
Leica Biosystems). Nephron size on biopsy was characterized
by mean nonsclerotic glomerular volume, cortex volume per
glomerulus (reciprocal of nonsclerotic glomerular volumetric
density), and mean cross-sectional tubular area as previously
described.21 Nephrosclerosis on biopsy was characterized by
the percentage of glomeruli that were globally sclerosed, the
percentage of interstitial fibrosis/tubular atrophy of the cortex
area, the number of distinct interstitial fibrosis/tubular atrophy
foci, and the severity of arteriosclerosis.21 The severity of arteriosclerosis was determined by the percentage of luminal stenosis due to intimal thickening in the small-medium artery (if
any present) most orthogonal to its axis. These were performed
by personnel unaware of the donors’ characteristics and outcomes. The presence of any arteriolar hyalinosis required a

© 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
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TABLE 4.

Long-term outcomes of asymptomatic stone formers vs non-stone formers
Outcomes,
mean ± SD or n (%)
Median follow-up (y)
Follow-up eGFR (mL/min/1.73 m2)
Residual eGFR %
eGFR <60 mL/min/1.73 m2
eGFR <45 mL/min/1.73 m2
Incident hypertension

Group 1: non-stone
formers (N = 778),
mean ± SD or N (%)
9.9 (7.5-13.0)
65.9 ± 16.0
75.5 ± 15.8
311 (40.0)
48 (6.2)
102 (13.1)

Group 2: asymptomatic
stones only (N = 76),
mean ± SD or N (%)

Unadjusted model
estimate

P

Adjusteda model
estimate

P

9.6 (7.2-12.4)
66.4 ± 17.3
77.0 ± 16.4
29 (38.2)
6 (7.9)
9 (11.8)

0.75 (−1.1 to 2.6)b
0.92 (0.57 to 1.5)c
1.30 (0.54 to 3.15)c
0.95 (0.49 to 1.85)c

0.43
0.76
0.56
0.87

0.65 (−1.2 to 2.5)b
1.02 (0.75 to 1.40)c
1.45 (0.83 to 2.56)c
1.02 (0.52 to 2.02)c

0.48
0.89
0.20
0.95

Adjusted for age, sex, and follow-up time.
Mean difference (95% CI).
c
Odds ratio (95% CI).
a

b

TABLE 5.

Long-term outcomes of symptomatic stone formers vs non-stone formers
Outcomes,
mean ± SD or n (%)
Median follow-up (y)
Follow-up eGFR (mL/min/1.73 m2)
Residual eGFR %
eGFR <60 mL/min/1.73 m2
eGFR <45 mL/min/1.73 m2
Incident hypertension

Group 1: non-stone
formers (N = 778),
mean ± SD or N (%)

Group 2: symptomatic
stone formers (N = 12),
mean ± SD or N (%)

Unadjusted model
estimate

P

Adjusteda model
estimate

9.9 (7.5-13.0)
65.9 ± 16.0
75.5 ± 15.8
311 (40.0)
48 (6.2)
102 (13.1)

9.7 (7.6-10.7)
69.2 (57.9-3.7)
92.3 (64.8-103.4)
3 (25)
1 (8.3)
3 (25.0)

6.53 (2.0-11.1)b
0.50 (0.13-1.86)c
1.38 (0.17-10.93)c
0.51 (0.07-3.97)c

0.005
0.30
0.76
0.52

7.18 (2.7-11.7)b
0.34 (0.09-1.38)c
1.08 (0.13-8.89)c
0.51 (0.06-4.03)c

P

0.002
0.13
0.94
0.52

Bolded P-values - significant for P < 0.05.
a
Adjusted for age, sex, and follow-up time.
b
Mean difference (95% CI).
c
Odds ratio (95% CI).

review of all 12 biopsy section slides by a pathologist to be
detected (data only available for Mayo Clinic Minnesota).
Predonation CT images from the angiogram/cortical phase
were downloaded onto a workstation for processing. The kidney cortical volumes were segmented using a semi-automated
algorithm (ITK-SNAP software, version 2.2; University of
Pennsylvania, Philadelphia, PA).21 Nephron number per kidney
was calculated from the product of cortical volume and nonsclerotic glomerular volumetric density as previously described.22
Donor Outcomes
Outcomes of donors were assessed by administered or
mailed survey and medical record query of donors in the Mayo
Clinic Health System for serum creatinine at least 5 y after
donation. Kidney function at follow-up was calculated by the
Chronic Kidney Disease-Epidemiology Collaboration (CKDEPI) equation. Other kidney function outcomes included
residual eGFR (follow-up eGFR/predonation eGFR × 100%),
eGFR <60 mL/min/1.73 m2, and eGFR <45 mL/min/1.73 m2.
Incident hypertension was assessed among those without predonation hypertension and defined by self-reported office systolic blood pressure ≥140 mm Hg, or diastolic blood pressure
≥90 mm Hg, or taking any new antihypertensive medication
for the purpose to lower the blood pressure after donation.
As reported previously, self-reported data have been validated
when compared to objective in available medical records.17,23
The survey was not designed to assess for stone recurrence
and not all SFs had medical records for review, thus stone
recurrence during follow-up was not assessed.

Statistical Analysis
Baseline clinical, microstructural, and macrostructural findings were reported as mean ± SD, or number (N) with percent
(%.). Measures of nephrosclerosis and nephron number were
dichotomized at the abnormal 95th (or fifth) percentiles for
age as previously identified.16 We assessed differences between
non-SFs and SFs by parametric and nonparametric analysis.
Clinical characteristics along with the presence or absence of
stone disease were used as covariates in regression models to
determine their association with long-term outcomes. Linear
regression was used to predict follow-up eGFR and residual
eGFR. Univariate and multivariable logistic regressions were
used to predict eGFR <60, eGFR <45 mL/min/1.73 m2, and
incident hypertension at follow-up. Odds ratios were calculated for both unadjusted models and models adjusted for
age, sex, and follow-up time. As a sensitivity analysis, non-SFs
were matched separately to asymptomatic SFs (4:1 matched)
and symptomatic SFs (2:1 matched) using a propensity score
calculated from baseline clinical characteristics. Variables with
missing values in the SFs were excluded from the propensity
score. Long-term outcomes were then assessed with the same
approach used for the unmatched analysis. Statistical analyses
were performed using JMP software version 14.0.

RESULTS
Donor Clinical and Structural Characteristics
Among 1660 donors who met inclusion criteria and were
alive at the time of survey evaluation, 866 donors had a
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TABLE 6.

TABLE 7.

Propensity-matched clinical characteristics by kidney
stone group

Clinical characteristics
Age (y)
Male
Caucasian
Predonation hypertension
Predonation SBP (mm Hg)
Predonation DBP (mm Hg)
Body mass index (kg/m2)
Obesity (BMI ≥ 30 kg/m2)
Total cholesterola
Triglyceridesa
HDL cholesterola
Fasting glucose
Metabolic syndrome
Bariatric surgery
History of urinary tract infections
Thiazide diuretic
Vitamin C supplement
Calcium supplement
Serum calcium (mg/dL)
Serum phosphorus (mg/dL)
Serum uric acid (mg/dL)
eGFR (mL/min/1.73 m2)
Measured GFR (mL/min/1.73 m2)a
24h urine albumin (mg)a
24h urine total protein (mg)a
24h urine volume (mL)a
24h urine volume <1000 mLa
Donor nephrectomy – right

Group 1:
Group 2:
non-stone
asymptomatic
formers (N = 152),
stone formers
mean ± SD
(N = 76),
or N (%)
mean ± SD or N (%)
45.5 ± 12.1
69 (45.4)
138 (90.8)
26 (17.1)
120.8 ± 14.9
74.3 ± 9.4
27.9 ± 4.5
24 (50.0)
194.8 ± 35.2
120.1 ± 73.4
56.6 ± 15.5
93.5 ± 8.6
32 (21.1)
0 (0)
11 (7.2)
12 (7.9)
9 (5.9)
17 (11.2)
9.5 ± 0.3
3.5 ± 0.8
5.4 ± 1.4
86.9 ± 15.6
102.6 ± 21.4
5.0 ± 6.8
47.9 ± 29.1
2273.1 ± 803.7
8 (5.3)
10 (20.8)

45.6 ± 11.6
29 (38.2)
70 (92.1)
15 (19.7)
121.8 ± 15.8
74.5 ± 10.2
28.1 ± 6.0
6 (50)
196.9 ± 36.4
131.2 ± 105.2
55.1 ± 14.8
93.8 ± 9.1
18 (23.7)
0 (0)
6 (7.9)
8 (10.5)
4 (5.3)
11 (14.5)
9.5 ± 0.4
3.5 ± 0.6
5.3 ± 1.5
86.4 ± 14.0
99.8 ± 16.8
4.2 ± 4.6
52.7 ± 43.2
2159.1 ± 822.1
5 (6.6)
2 (16.7)

Propensity-matched clinical characteristics by kidney
stone group

Clinical characteristics

Group 1:
non-stone
formers (N = 48),
mean ± SD
or N (%)

Age (y)
Male
Caucasian
Predonation hypertension
Predonation SBP (mm Hg)
Predonation DBP (mm Hg)
Body mass index (kg/m2)
Obesity (BMI ≥ 30 kg/m2)
Total cholesterol
Triglycerides
HDL cholesterol
Fasting glucose
Metabolic syndrome
Bariatric surgery
History of urinary tract infections
Thiazide diuretic
Vitamin C supplement
Calcium supplement
Serum calcium (mg/dL)
Serum phosphorus (mg/dL)
Serum uric acid (mg/dL)
eGFR (mL/min/1.73 m2)
Measured GFR (mL/min/1.73 m2)a
24h urine albumin (mg)a
24h urine total protein (mg)
24h urine volume (mL)a
24h urine volume <1000 mLa
Donor nephrectomy – right

48.1 ± 9.9
24 (50.0)
48 (100)
5 (10.4)
121.9 ± 14.2
74.5 ± 9.4
30.0 ± 5.0
24 (50.0)
192.5 ± 32.0
139.3 ± 84.8
55.2 ± 16.8
101.5 ± 12.0
15 (31.2)
0 (0)
8 (16.7)
0 (0)
0 (0)
9 (18.8)
9.5 ± 0.3
3.5 ± 0.5
4.8 ± 1.2
85.3 ± 15.1
100.8 ± 19.4
4.9 ± 7.4
54.2 ± 33.4
2033.3 ± 814.6
6 (12.5)
10 (20.8)

Group 3:
symptomatic
stone formers
(N = 12), mean ± SD
or N (%)
50.5 ± 10.4
7 (58.3)
12 (100)
2 (16.7)
126.3 ± 11.3
73.4 ± 10.7
30.5 ± 5.9
6 (50)
190.4 ± 33.8
157.7 ± 208.9
54.5 ± 17.3
100.8 ± 19.4
4 (33.3)
1 (8.3)
2 (16.7)
0 (0)
0 (0)
3 (25.0)
9.5 ± 0.4
3.5 ± 1.1
5.3 ± 1.6
81.3 ± 10.5
95.1 ± 10.7
4.0 ± 3.7
58.3 ± 44.0
2264.3 ± 798.8
1 (8.3)
2 (16.7)

a

Variables not used included in propensity matching due to missing data in the asymptomatic
stone formers group.
Non-stone formers (N = 152) were matched 2:1 to asymptomatic stone formers (N = 76) using
a propensity score calculated from these baseline clinical characteristics.
BMI, body mass index; DBP, diastolic blood pressure; GFR, glomerular filtration rate; HDL, highdensity lipoprotein; SBP, systolic blood pressure.

a

long-term follow-up serum creatinine (Figure 1). There were
778 non-SFs, 76 asymptomatic SFs, and 12 symptomatic
SFs. Nearly all baseline clinical characteristics were similar
(Table 1). Asymptomatic SFs were more likely to take a thiazide diuretic for the treatment of hypertension. Symptomatic
SF had less artery luminal stenosis. Nearly all baseline structural characteristics were also similar (Table 2). Non-SFs were
less likely to have MSK than asymptomatic SFs.

1–12) in asymptomatic SFs and 0.42 ± 0.99 (range 0–3) in
symptomatic SFs. The asymptomatic SFs with 12 stones had
only very small (<1 mm) bilateral calcifications in the setting
of MSK of unclear significance. The lower pole was the most
common location for stone(s) in asymptomatic SFs. Two SFs
received targeted medical therapy for stone prevention before
donation. The stone composition was known in 4 symptomatic SFs, and all were primarily calcium-based. Urine pH
was <5.5 or >6.5 in 32.9% of SF. Over half (53.4%) of SFs had
at least 1 valid 24 h urine SS study for evaluation. The most
common abnormalities were elevated calcium phosphate SS
(37.5%), hypercalciuria (29.8%), hyperuricosuria (22.5%),
elevated urine sodium (21.9%), and hypocitraturia (15.2%).
One donor received hydrochlorothiazide for hypercalciuria
and 1 donor received potassium citrate for hypocitraturia
with normalization of these parameters before donation.

Characteristics of Stone Disease Among SFs
Symptomatic SFs reported a mean 1.4 ± 0.7 prior symptomatic (range 1–3) episodes, with 4 (25%) reporting at ≥2
episodes. One donor required shockwave lithotripsy to facilitate stone passage while the remaining donors passed stone(s)
spontaneously. The mean time from the last symptomatic
stone event to kidney donation was 11.1 ± 5.5 (range 3–20)
y. Family history of kidney stone disease among all SF was
13.6%. Two symptomatic SFs had bilateral kidney stones,
whereas the remaining symptomatic SFs were stone-free
(Table 3). The mean number of stones was 1.6 ± 1.7 (range

Variables not used included in propensity matching due to missing data in the symptomatic
stone formers group. SBP, systolic blood pressure.
Non-stone formers (N = 48) were matched 4:1 to symptomatic stone formers (N = 12) using a
propensity score calculated from baseline clinical characteristics.
BMI, body mass index; DBP, diastolic blood pressure; GFR, glomerular filtration rate; HDL, highdensity lipoprotein.

Stone Characteristics at Time of Donation
At the time of kidney donation, asymptomatic SFs were
more likely to undergo right nephrectomy than non-SFs

© 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
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TABLE 8.

Long-term outcomes in asymptomatic stone formers and propensity-matched non-stone formers (as shown in Table 6)

Outcomes
Follow-up (y), median (IQR)
Follow-up eGFR (mL/min/1.73 m2)
Residual eGFR %
eGFR <60 mL/min/1.73 m2
eGFR <45 mL/min/1.73 m2
Incident hypertension

Group 1: non-stone
formers (N = 152),
mean ± SD or N (%)
10.5 (8.3-13.4)
65.5 ± 16.1
76.4 ± 17.9
62 (40.8)
13 (8.6)
14 (9.2)

Group 2: asymptomatic
stone formers (N = 76),
mean ± SD or N (%)
9.6 (7.2-12.4)
66.4 ± 17.3
77.0 ± 16.4
29 (38.2)
6 (7.9)
9 (11.8)

Unadjusted model
estimate

P

Adjusteda model
estimate

0.66 (−4.14 to 5.46)b
0.90 (0.51 to 1.58)c
0.92 (0.33 to 2.51)c
1.32 (0.55 to 3.21)c

0.791
0.702
0.865
0.535

1.56 (−3.22 to 6.32)b
0.86 (0.46 to 1.59)c
0.79 (0.27 to 2.27)c
1.29 (0.52 to 3.20)c

P

0.523
0.624
0.658
0.576

Adjusted for age, sex, and follow-up time.
Mean difference (95% CI).
c
Odds ratio (95% CI).
a

b

TABLE 9.

Long-term outcomes in symptomatic stone formers and propensity-matched non-stone formers (as shown in Table 7)

Outcomes
Follow-up (y), median (IQR)
Follow-up eGFR (mL/min/1.73 m2)
Residual eGFR %
eGFR <60 mL/min/1.73 m2
eGFR <45 mL/min/1.73 m2
Incident hypertension

Group 1: non-stone
formers (N = 48),
mean ± SD or N (%)
9.9 (8.4-12.1)
66.4 ± 15.6
78.9 ± 17.8
20 (41.7)
2 (4.2)
7 (14.6)

Group 3: symptomatic
stone formers (N = 12),
mean ± SD or N (%)

Unadjusted model
estimate

P

Adjusteda model
estimate

P

9.7 (8.2-10.4)
70.2 ± 16.4
88.6 ± 28.3
3 (25.0)
1 (8.3)
3 (25.0)

9.65 (−3.16 to 22.45)b
0.47 (0.11 to 1.94)c
2.09 (0.17 to 25.2)c
1.95 (0.42 to 9.04)c

0.145
0.295
0.561
0.392

10.17 (−2.91 to 23.25)b
0.32 (0.07 to 1.53)c
1.49 (0.10 to 21.10)c
2.20 (0.42 to 11.38)c

0.133
0.155
0.770
0.348

Adjusted for age, sex, and follow-up time.
Mean difference (95% CI).
Odds ratio (95% CI).

a

b
c

(30.3% versus 19.2%, P = 0.02). Overall, 61 of 78 (78%) SFs
with a stone on donor CT (76 asymptomatic SFs and 2 symptomatic SFs) donated a kidney containing stone(s). Therefore,
13 SFs that had bilateral stones at baseline and 17 additional
asymptomatic SF were left with a kidney containing stone(s).
Long-term Outcomes of Living Kidney Donors
Over a median follow-up of 9.9 (7.5-12.9) y, no donors
reached end-stage renal disease (whether requiring dialysis or
kidney transplantation). The mean follow-up eGFR was 66.0
± 16.1 mL/min/1.73 m2, residual eGFR was 75.8%, 55 (6.4%)
donors had eGFR <45 mL/min/1.73 m2, 523 (60.3%) donors
had eGFR <60 mL/min/1.73 m2, and 114 (13.1%) developed
incident hypertension.
When compared with non-SFs, asymptomatic SFs had
similar long-term outcomes including residual eGFR, eGFR
<60 mL/min/1.73 m2, eGFR <45 mL/min/1.73 m2, and incident
hypertension in unadjusted and adjusted analysis (Table 4).
Symptomatic SFs had a higher residual eGFR than nonSFs in both unadjusted (P = 0.005) and unadjusted analysis
(P = 0.002) (Table 5). There was otherwise no association
between symptomatic SFs and eGFR <60 mL/min/1.73 m2,
eGFR <45 mL/min/1.73 m2, or incident hypertension.
As a sensitivity analysis, SFs were matched to non-SFs
with a propensity score based on baseline characteristics
(Tables 6 and 7). After propensity matching, risk of CKD
outcomes did not differ between asymptomatic SFs and
non-SFs (Table 8) or between symptomatic SFs and non-SFs
(Table 9).

DISCUSSION
In this study, we found that the postdonation renal outcomes
of SFs as compared with non-SFs were similar. Moreover, SFs
and non-SFs had similar GFR at baseline as well as microstructural findings on the implantation biopsy. Abnormal 24 h
urine studies were common in SFs. At a median follow-up of
10 y, all outcomes including eGFR and incident hypertension
were similar. SFs were not at increased risk for reduced GFR
or incident hypertension when compared to non-SFs.
In previous studies of 1957 potential donors at Mayo Clinic,
nephrolithiasis was the most common nonvascular anatomical
variation or abnormality on CT scan.2,18 In those studies, the
baseline clinical characteristics were similar between potential non-SFs and asymptomatic SFs; however, symptomatic SF
were more likely to be older, be hypertensive, and have higher
albuminuria. The SFs overall had lower urine volume and more
macrostructural abnormalities, including MSK, parenchymal
thinning, and focal scarring.2 In our study, which included only
approved donors, many of these findings were similar between
groups, although asymptomatic SFs were more likely to take a
thiazide diuretic for hypertension. It is likely potential donors
with more significant abnormalities were excluded from donation including those with albuminuria.
Nearly all structural characteristics on the implantation
renal biopsy were similar between non-SFs and SFs in this
study. MSK was more common in asymptomatic SFs; however,
the overall prevalence was low. Although MSK is associated
with kidney stone formation, MSK is often diagnosed during
the donor evaluation, even in the absence of stone formation
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and with a normal metabolic evaluation.24 Carefully selected
donors with MSK have excellent long-term outcomes, especially when compared with nondonors with MSK.24
In our study, we did not find an association with any manifestation of kidney stone disease and postdonation reduced
GFR in the intermediate to long term. This finding is somewhat unexpected given previous studies in the general population that have shown an association between nephrolithiasis
and subsequent chronic kidney disease and end-stage renal
disease.3,5,25,26 However, our findings are similar to a recent
large study that showed that selected donors with a history of
kidney stones had similar long-term outcomes to a matched
cohort.27 There are many plausible explanations for these
findings. Not all SFs are permitted to donate, and thus, the
donor evaluation may successfully exclude higher risk SFs
for CKD from donation. Although comorbidities including
predonation hypertension, obesity, and metabolic syndrome
were relatively common at baseline in this study, these findings were either mild or well-controlled and ultimately did not
exclude donors from donating a kidney.
In this study, we found a higher residual eGFR among symptomatic SFs. The explanation for this finding is unclear, but it
is possible a symptomatic SF has a high propensity to develop
glomerular hyperfiltration after donation. Even so, hyperfiltration after donation is not clearly harmful.28 Although we
did not assess split renal function at baseline and could not
confirm which kidney was affected by prior stone event(s) in
all symptomatic SFs, they may have donated a kidney with
lower contribution to the predonation GFR. Alternatively,
there may be more selection toward health in selection of
donors with a history of symptomatic stones, which is further
supported by the less severe arteriosclerosis on biopsy (lower
% artery luminal stenosis).
Although the overall stone burden in SFs was low, select SFs
with multiple prior symptomatic stone events, bilateral stone
disease, and MSK were allowed to donate. Abnormal 24 h
urine chemistries were common among SFs that underwent
24 h urine evaluation before donation, similar to previously
published literature.14 Published guidelines recommend against
donation if these findings are present during the donor evaluation.11 The latter recommendation of a normal metabolic evaluation is not in keeping with prior literature that has shown
that 24 h urine studies do not reliably predict recurrence.29
However, all SFs in our study received education regarding
dietary interventions and increasing urinary volume, which
have been shown to reduce future risk of stone events.
This study has many strengths with findings that have not
been previously described, including a long-term follow-up
study of well-described symptomatic and asymptomatic SFs.
We included comprehensive stone histories and metabolic evaluations as well as extensive comparisons of clinical, structural,
and histologic data with non-SFs. In particular, we found that
baseline histology was similar and favorable between SFs and
non-SFs, which may help to explain comparable GFR longterm. We do acknowledge several limitations including a predominantly Caucasian donor population and lack of data on
kidney stone recurrence. The sample of symptomatic SFs was
relatively small and heterogeneous, which makes generalizability difficult. Nevertheless, few prior studies have compared this
group of SFs with non-SFs and their outcomes overall were
favorable. Although a median follow-up of 10 y may be insufficient to detect donors reaching end-stage renal disease, this

study includes some of the longest follow-up of donors with
history of kidney stones and provides encouraging data that
the incidence of lower GFR was modest and similar between
groups. Our study was not designed to assess stone recurrence.
Other studies have suggested that recurrence of stone events
is low even in the intermediate to long-term postdonation.14,30
Although not all SF underwent a metabolic evaluation, this
deficiency is seen in prior studies, and recommendations for
obtaining 24 h urine studies have evolved over time.11,14
In conclusion, long-term renal outcomes between SF and
non-SF living kidney donors are similar. SFs with a low stone
burden at baseline and symptomatic SFs with a remote history of their past symptomatic stone events are at low risk
for decreased GFR or incident hypertension. We recommend a
thorough evaluation of kidney stone risk factors coupled with
collaboration between the transplant providers and a nephrologist specializing in stone disease when available to provide
a more thorough risk assessment for kidney stone recurrence.
Interventions to reduce stone risk are also indicated.
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